Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
301 hedge funds and large institutions have $2.74B invested in Amedisys in 2023 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 86 increasing their positions, 107 reducing their positions, and 50 closing their positions.
42% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 50
18% more capital invested
Capital invested by funds: $2.32B → $2.74B (+$423M)
7% more funds holding
Funds holding: 281 → 301 (+20)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.64% less ownership
Funds ownership: 96.6% → 91.96% (-4.6%)
20% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 107
25% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $23.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$57.9M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$45.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$39.6M |
| 4 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$35.9M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$27.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$83.3M |
| 2 |
JP Morgan Chase
New York
|
-$73.9M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
-$42M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$40M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$29.4M |
AMED Hedge Fund Activity: Q2 2023 in Review
301 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2023, worth a combined $2.74B — up 18% from $2.32B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new AMED positions and 50 closed out — a net gain of 21 holders — while 86 added to existing stakes and 107 trimmed.
The largest buyer was Alpine Associates Management, opening a new position worth an estimated $57.9M. The largest seller was Wellington Management Group, cutting an estimated $83.3M.
- 301 institutional investors held Amedisys (AMED) as of Q2 2023, up from 281 in Q1 2023.
- Funds reported $2.74B of Amedisys stock for Q2 2023, up 18% quarter-over-quarter.
- 71 funds opened new Amedisys positions in Q2 2023 and 50 closed out, a net change of +21 holders.
- The largest Amedisys buyer in Q2 2023 was Alpine Associates Management, an estimated $57.9M added.
- The largest Amedisys seller in Q2 2023 was Wellington Management Group, an estimated $83.3M sold.
Based on aggregated 13F filings for Q2 2023.